Inhibitor Therapeutics, Inc. (INTI) Stock Price & Analysis
Inhibitor Therapeutics, Inc. (INTI) rose 0.00% to USD 0.09 as of July 25, 2026 at 20:52 UTC, according to Nexqual real-time market data.
INTI last closed at USD 0.09; the session ranged USD 0.08–0.08 on volume of 20,000 shares. Market capitalization is $15.01M, with a 52-week range of USD 0.04–0.12 (OQB). Source: Nexqual, July 25, 2026 at 20:52 UTC.
Key Statistics (as of July 25, 2026 at 20:52 UTC)
| Price | USD 0.09 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0.09 |
| Open | USD 0.08 |
| Day Range | USD 0.08 – 0.08 |
| 52-Week Range | USD 0.04 – 0.12 |
| Volume | 20,000 shares |
| Market Cap | $15.01M |
| Exchange | OQB |
Technical Analysis (INTI)
Nexqual's technical model rates INTI "BUY" based on 4 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 20:52 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 66.62 (neutral) |
| vs SMA50 | Above (USD 0.08) |
| MACD | -0 (negative) |
Analyst Ratings (INTI)
Wall Street analysts rate INTI "None", per Nexqual as of July 25, 2026 at 20:52 UTC.
| Consensus Rating | None |
|---|
Earnings (INTI)
Source: Nexqual, July 25, 2026 at 20:52 UTC.
Financials & Fundamentals (INTI)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 3.6 |
| Total Cash | $1.29M |
| Total Debt | $58,361 |
| Free Cash Flow | $-1.83M |
Source: Nexqual, July 25, 2026 at 20:52 UTC.
Financial Health Score (INTI)
Nexqual rates Inhibitor Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 20:52 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Mixed — $1M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$3M |
| Efficiency | Mixed — No data |
Ownership (INTI)
| Insider Ownership | +57.16% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 172.57M |
| Float | 77.56M |
| Short % of Float | +0.36% |
Source: Nexqual, July 25, 2026 at 20:52 UTC.
Leadership (INTI)
Inhibitor Therapeutics, Inc. is led by Francis E. O'Donnell Jr. (age 75), Founder, Executive Chairman & CEO, per Nexqual as of July 25, 2026 at 20:52 UTC.
| Founder, Executive Chairman & CEO | Francis E. O'Donnell Jr. (age 75) |
|---|---|
| Interim CFO, Treasurer & Secretary | James A. McNulty (age 75) |
From Inhibitor Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States.
- It engages in the development of therapies initially for basal cell carcinoma nevus syndrome (BCCNS) cancers by utilizing itraconazole; development of therapies initially for basal cell carcinoma (BCC) cancers; and SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CLRN | CLARENT CORP | USD 0 | ▲ 0% |
| ATGN | Altigen Communications, Inc. | USD 0.47 | ▼ 2.08% |
| MWAI | MedwellAI, Inc. | USD 0.37 | ▲ 0% |
| CLST | Catalyst Bancorp, Inc. | USD 16.6 | ▼ 1.89% |
| ASPT | ALADDIN SEPARATION TECHNOLOGIES | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 20:52 UTC. This page is informational and not investment advice.